These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31820847)

  • 21. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.
    Wijarnpreecha K; Thongprayoon C; Scribani M; Ungprasert P; Cheungpasitporn W
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):404-410. PubMed ID: 29215435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease.
    Song DS; Chang UI; Kang SG; Song SW; Yang JM
    Gut Liver; 2019 Nov; 13(6):658-668. PubMed ID: 30970434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Nadinskaia M; Maevskaya M; Ivashkin V; Kodzoeva K; Pirogova I; Chesnokov E; Nersesov A; Kaibullayeva J; Konysbekova A; Raissova A; Khamrabaeva F; Zueva E
    World J Gastroenterol; 2021 Mar; 27(10):959-975. PubMed ID: 33776366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
    Kim D; Kim WR; Kim HJ; Therneau TM
    Hepatology; 2013 Apr; 57(4):1357-65. PubMed ID: 23175136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease.
    Yari FA; Shabani P; Karami S; Sarmadi N; Poustchi H; Bandegi AR
    BMC Endocr Disord; 2021 Aug; 21(1):153. PubMed ID: 34344333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive liver fibrosis markers are independently associated with carotid atherosclerosis risk in patients with nonalcoholic fatty liver disease.
    Su J; Zhou L; Liu J; Wang Y; Wang G
    Scand J Gastroenterol; 2024 Aug; 59(8):961-971. PubMed ID: 38907624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease.
    Zuo G; Xuan L; Xin Z; Xu Y; Lu J; Chen Y; Dai M; Zhang D; Wang W; Li M; Bi Y; Ning G; Xu M
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e3957-e3968. PubMed ID: 34125886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China.
    Yu X; Chen C; Guo Y; Tong Y; Zhao Y; Wu L; Sun X; Wu X; Song Z
    Ann Med; 2021 Dec; 53(1):1621-1631. PubMed ID: 34498502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atherosclerosis and Associated Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.
    Bajaj S; Prajapati SK
    J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency of Nonalcoholic Fatty Liver Disease and Subclinical Atherosclerosis Among Young Mexican Americans.
    Gill C; Vatcheva KP; Pan JJ; Smulevitz B; McPherson DD; Fallon M; McCormick JB; Fisher-Hoch SP; Laing ST
    Am J Cardiol; 2017 Jun; 119(11):1717-1722. PubMed ID: 28395890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,380 adults using serial echocardiography.
    Kim G; Yu TY; Jee JH; Bae JC; Kang M; Kim JH
    Diabetes Metab; 2024 May; 50(3):101534. PubMed ID: 38608865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic Fatty Liver Disease Is Associated With Arterial Distensibility and Carotid Intima-Media Thickness: (from the Multi-Ethnic Study of Atherosclerosis).
    Oni E; Budoff MJ; Zeb I; Li D; Veledar E; Polak JF; Blankstein R; Wong ND; Blaha MJ; Agatston A; Blumenthal RS; Nasir K
    Am J Cardiol; 2019 Aug; 124(4):534-538. PubMed ID: 31262497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association of low-grade albuminuria with incident non-alcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycaemia status.
    Xin Z; Liu S; Niu J; Xu M; Wang T; Lu J; Chen Y; Wang W; Ning G; Bi Y; Xu Y; Li M; Zhao Z
    Liver Int; 2021 Jan; 41(1):101-109. PubMed ID: 32840963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis.
    Jung CH; Rhee EJ; Kwon H; Chang Y; Ryu S; Lee WY
    Endocrinol Metab (Seoul); 2020 Mar; 35(1):165-176. PubMed ID: 32207277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The synergistic impact of nonalcoholic fatty liver disease and metabolic syndrome on subclinical atherosclerosis.
    Hong HC; Hwang SY; Ryu JY; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
    Clin Endocrinol (Oxf); 2016 Feb; 84(2):203-209. PubMed ID: 26342196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral Artery Disease and Risk of Fibrosis Deterioration in Nonalcoholic Fatty Liver Disease: A Prospective Investigation.
    Zhu W; Deng CJ; Xuan LP; Dai HJ; Zhao ZY; Wang TG; Li M; Lu JL; Xu Y; Chen YH; Wang WQ; Bi YF; Xu M
    Biomed Environ Sci; 2020 Apr; 33(4):217-226. PubMed ID: 32438959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.
    Baratta F; Pastori D; Angelico F; Balla A; Paganini AM; Cocomello N; Ferro D; Violi F; Sanyal AJ; Del Ben M
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2324-2331.e4. PubMed ID: 31887443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.